Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-160X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada ; volume:39 ; number:9 ; day:25 ; month:6 ; year:2019 ; pages:1621-1630 ; date:9.2019
Rheumatology international ; 39, Heft 9 (25.6.2019), 1621-1630, 9.2019
- Creator
-
Foo, Jason
Morel, Chaienna
Bergman, Martin
Baerwald, Christoph
Rodriguez-Heredia, José Manuel
Marshall, Alexander
Polanco-Sánchez, Carlos
Postema, Roelien
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00296-019-04352-2
- URN
-
urn:nbn:de:101:1-2019122802435474592491
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Foo, Jason
- Morel, Chaienna
- Bergman, Martin
- Baerwald, Christoph
- Rodriguez-Heredia, José Manuel
- Marshall, Alexander
- Polanco-Sánchez, Carlos
- Postema, Roelien
- SpringerLink (Online service)
Other Objects (12)
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis
Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Reduced progression of bone erosion in cytomegalovirus seropositive rheumatoid arthritis patients
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)